Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Mary Imogene Bassett Hospital — Cooperstown, New York
- The Cancer Institute at Saint Francis Hospital — East Hills, New York
- Arnot Ogden Medical Center/Falck Cancer Center — Elmira, New York
Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in New York: - Hematology Oncology Associates of Central New York-Auburn — Auburn, New York
- Northwell Health Imbert Cancer Center — Bay Shore, New York
- Maimonides Medical Center — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- The Cancer Institute at Saint Francis Hospital — East Hills, New York
- Glens Falls Hospital — Glens Falls, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in New York: - Wilmot Cancer Center at Batavia — Batavia, New York
- Northwell Health Imbert Cancer Center — Bay Shore, New York
- Sands Cancer Center — Canandaigua, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in New York: - Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Sands Cancer Center — Canandaigua, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in New York: - Glens Falls Hospital — Glens Falls, New York
- Upstate Cancer Center at Oswego — Oswego, New York
- University of Rochester — Rochester, New York
- Stony Brook University Medical Center — Stony Brook, New York
- State University of New York Upstate Medical University — Syracuse, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Memorial Sloan Kettering Commack — Commack, New York
- The New York Hospital Medical Center of Queens — Flushing, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in New York: - Albany Medical Center — Albany, New York
- Maimonides Medical Center — Brooklyn, New York
- The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Mount Sinai Hospital — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in New York: - Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in New York: - Clinical Study Site — New York, New York
- Clinical Study Site — Syracuse, New York
- Clinical Site — The Bronx, New York
Phase 3 Recruiting Industry
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…
Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in New York: - New York Cancer & Blood Specialists - Babylon Medical Oncology — Babylon, New York
- Optum Medical Care - Carmel/Brewster Campus — Brewster, New York
- Brooklyn Radiation Oncology — Brooklyn, New York
- Optum Medical Care - Fishkill Westage Campus — Fishkill, New York
- Clinical Research Alliance — Lake Success, New York
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in New York: - Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
- Mount Sinai Hospital — New York, New York
- Manhattan Eye Ear and Throat Hospital — New York, New York
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in New York: - New York Oncology Hematology, P.C. ( Site 4012) — Albany, New York
- Memorial Sloan-Kettering Cancer Center at Commack ( Site 4055) — Commack, New York
- Memorial Sloan Kettering - Westchester ( Site 4058) — Harrison, New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095) — Mineola, New York
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 4053) — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in New York: - Research Site — Stony Brook, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in New York: - NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in New York: - Local Institution - 0678 — Cooperstown, New York
- Ellis Hospital — Schenectady, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in New York: - Roswell Park Cancer Institute ( Site 0184) — Buffalo, New York
- Hematology-Oncology Associates of CNY ( Site 0164) — East Syracuse, New York
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) — New York, New York
- Icahn School of Medicine at Mount Sinai ( Site 0116) — New York, New York
- Memorial Sloan Kettering Cancer Center ( Site 0137) — New York, New York
Phase 3 Recruiting Industry
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in New York: - Cayuga Medical Center ( Site 0086) — Ithaca, New York
- University Hospital at Stony Brook ( Site 0054) — Stony Brook, New York
- White Plains Hospital ( Site 0091) — White Plains, New York
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in New York: - Maimonides Medical Center /ID# 240783 — Brooklyn, New York
- Northwell Health - Monter Cancer Center /ID# 247081 — Lake Success, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in New York: - WMCHealth Advanced Physician Services — Hawthorne, New York
- Local Institution - 0128 — Rochester, New York
- Local Institution - 0518 — Schenectady, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in New York: - Local Institution - 0224 — Laurelton, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Optum Medical Care, PC — Westbury, New York
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in New York: - Suny-Stony Brook University Cancer Center — Stony Brook, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in New York: - New York Cancer & Blood Specialists (NYCBS) — New Hyde Park, New York
- New York Cancer & Blood Specialists (NYCBS) — New York, New York
- University of Rochester Medical Center — Rochester, New York
- New York Cancer & Blood Specialists (NYCBS) — Shirley, New York
- New York Cancer & Blood Specialists (NYCBS) — The Bronx, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in New York: - Stony Brook University Medical Center — Stony Brook, New York
Phase 3 Recruiting Industry
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in New York: - Research Site — New York, New York
- Research Site — New York, New York
- Research Site — The Bronx, New York